Lysine specific demethylase 1 inhibitor - Decoy Therapeutics
Alternative Names: LSD1i - Decoy TherapeuticsLatest Information Update: 27 Nov 2025
At a glance
- Originator Salarius Pharmaceuticals
- Developer Decoy Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Lysine specific demethylase 1 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Haematological malignancies; Solid tumours
Most Recent Events
- 13 Nov 2025 Salarius Pharmaceuticals has merged with Decoy Therapeutics to form Decoy Therapeutics
- 31 Dec 2021 Early research in Haematological malignancies in USA (unspecified route) (3659809; Salarius Pharmaceuticals pipeline, April 2022)
- 31 Dec 2021 Early research in Solid tumours in USA (unspecified route) (3659809; Salarius Pharmaceuticals pipeline, April 2022)